Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotic Bifidobacterium lactis V9 plus immune checkpoint inhibitor and platinum-based chemotherapy in advanced NSCLC
ChiCTR2600126856Phase 2Completed
- Sponsor
- Inner Mongolia Autonomous Region People's Hospital
- Start
- Jun 2026
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Bifidobacterium animalis subsp. lactis V9 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Inner Mongolia Autonomous Region People's Hospital. Primary endpoints: Serum cytokine levels (IL-17A, TNF-α, IL-6, IL-8, IFN-γ), Intestinal mucosal barrier markers (D-lactate, diamine oxidase, endotoxin) and 4 more. Started Jun 2026; status: completed.
02
Drugs
Bifidobacterium animalis subsp. lactis V9
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600126856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126856.